UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 43

Sortiert nach

Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma

Current cancer drug targets, 2016-03, Vol.16 (3), p.261

2016

Volltextzugriff (PDF)

Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies

Cancers, 2021-06, Vol.13 (12), p.2878

2021

Volltextzugriff (PDF)

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact

International journal of molecular sciences, 2020-06, Vol.21 (13), p.4659

2020

Volltextzugriff (PDF)

Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells

PloS one, 2016-11, Vol.11 (11), p.e0166233-e0166233

2016

Volltextzugriff (PDF)

Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing

International journal of molecular sciences, 2022-10, Vol.23 (19), p.11787

2022

Volltextzugriff (PDF)

Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma

International journal of molecular sciences, 2023-01, Vol.24 (1), p.799

2023

Volltextzugriff (PDF)

Single-nucleotide polymorphism profiling by multimodal-targeted next-generation sequencing in methotrexate-resistant and -sensitive human osteosarcoma cell lines

Frontiers in pharmacology, 2023, Vol.14, p.1294873-1294873

2023

Volltextzugriff (PDF)

Cisplatin Resistance in Osteosarcoma: In vitro Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments

Frontiers in oncology, 2020-03, Vol.10, p.331-331

2020

Volltextzugriff (PDF)

Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors

Cells (Basel, Switzerland), 2020-04, Vol.9 (4), p.968

2020

Volltextzugriff (PDF)

Impact of ABC Transporters in Osteosarcoma and Ewing’s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?

Cells (Basel, Switzerland), 2021-09, Vol.10 (9), p.2461

2021

Volltextzugriff (PDF)

ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma

Cells (Basel, Switzerland), 2020-03, Vol.9 (3), p.647

2020

Volltextzugriff (PDF)

Xenografting Human Musculoskeletal Sarcomas in Mice, Chick Embryo, and Zebrafish: How to Boost Translational Research

Biomedicines, 2024-08, Vol.12 (8), p.1921

2024

Volltextzugriff (PDF)

Effect of TP53 Arg72Pro and MDM2 SNP309 Polymorphisms on the Risk of High-Grade Osteosarcoma Development and Survival

Clinical cancer research, 2009-05, Vol.15 (10), p.3550-3556

2009

Volltextzugriff (PDF)

Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma

Expert opinion on drug metabolism & toxicology, 2015-01, Vol.11 (9), p.1449-1463

2015

Volltextzugriff (PDF)

An update on emerging drugs in osteosarcoma: towards tailored therapies?

Expert opinion on emerging drugs, 2019-07, Vol.24 (3), p.153-171

2019

Volltextzugriff (PDF)

Polymorphisms of genes related to metotrexate response and toxicity in high-grade osteosarcoma

Expert opinion on drug metabolism & toxicology, 2017-01, Vol.13 (1), p.123-123

2017

Volltextzugriff (PDF)

Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts

Cancer letters, 2019-08, Vol.456, p.29-39

2019

Volltextzugriff (PDF)

Targeting Glutathione-S Transferase Enzymes in Musculoskeletal Sarcomas: A Promising Therapeutic Strategy

Analytical cellular pathology (Amsterdam), 2011-01, Vol.34 (3), p.131-145

2011

Volltextzugriff (PDF)

Advances in emerging drugs for osteosarcoma

Expert opinion on emerging drugs, 2015-09, Vol.20 (3), p.495-514

2015

Volltextzugriff (PDF)

Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment

Expert opinion on drug metabolism & toxicology, 2019-04, Vol.15 (4), p.299-311

2019

Volltextzugriff (PDF)

Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?

Expert review of molecular diagnostics, 2018-11, Vol.18 (11), p.947-961

2018

Volltextzugriff (PDF)

Emerging drugs for high-grade osteosarcoma

Expert opinion on emerging drugs, 2010-12, Vol.15 (4), p.615-634

2010

Volltextzugriff (PDF)

Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy

The pharmacogenomics journal, 2012-12, Vol.12 (6), p.476-483

2012

Volltextzugriff (PDF)

Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma

Cancer research (Chicago, Ill.), 2008-08, Vol.68 (16), p.6661-6668

2008

Volltextzugriff (PDF)

Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma

Expert opinion on drug metabolism & toxicology, 2017-03, Vol.13 (3), p.245-257

2017

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(42)
Buchkapitel
(1)

Sprache

Englisch
(43)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma

Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact

Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells

Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing

Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma

Single-nucleotide polymorphism profiling by multimodal-targeted next-generation sequencing in methotrexate-resistant and -sensitive human osteosarcoma cell lines

Cisplatin Resistance in Osteosarcoma: In vitro Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments

Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors

Impact of ABC Transporters in Osteosarcoma and Ewing’s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?

ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma

Xenografting Human Musculoskeletal Sarcomas in Mice, Chick Embryo, and Zebrafish: How to Boost Translational Research

Effect of TP53 Arg72Pro and MDM2 SNP309 Polymorphisms on the Risk of High-Grade Osteosarcoma Development and Survival

Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma

An update on emerging drugs in osteosarcoma: towards tailored therapies?

Polymorphisms of genes related to metotrexate response and toxicity in high-grade osteosarcoma

Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts

Targeting Glutathione-S Transferase Enzymes in Musculoskeletal Sarcomas: A Promising Therapeutic Strategy

Advances in emerging drugs for osteosarcoma

Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment

Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?

Emerging drugs for high-grade osteosarcoma

Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy

Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma

Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma

Suchergebnisse filtern